AEZS Stock Performance, Insider Transaction and News

AEZS - Aeterna Zentaris Inc.

Market Cap	14.50M	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-18.05M	Forward P/E	-1.09	EPS next Y	-	50D Avg Chg	4.00%
Sales	2.37M	PEG	-	EPS past 5Y	-	200D Avg Chg	-8.00%
Dividend	N/A	Price/Book	0.46	EPS next 5Y	-	52W High Chg	-50.00%
Recommedations	-	Quick Ratio	5.68	Shares Outstanding	3.06M	52W Low Chg	28.00%
Insider Own	1.59%	ROA	-29.96%	Shares Float	1.12M	Beta	2.16
Inst Own	6.26%	ROE	-81.71%	Shares Shorted/Prior	409/-	Price	2.97
Gross Margin	90.69%	Profit Margin	-	Avg. Volume	10,153	Target Price	-
Oper. Margin	-152,750.00%	Earnings Date	Aug 7	Volume	5,977	Change	0.34%

Healthcare | Biotechnology | Canada

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Aeterna Zentaris Inc. News

06/13/24	Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
06/03/24	Aeterna Zentaris and Ceapro Complete Merger Transaction
05/29/24	Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
05/29/24	Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger
05/17/24	Aeterna Zentaris Finalizes Some Details for Ceapro Merger
05/17/24	Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
05/14/24	MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden
05/14/24	Aeterna Zentaris Reports First Quarter 2024 Financial Results
05/01/24	Aeterna Zentaris Announces Effective Date of Share Consolidation
04/28/24	12 ChatGPT Penny Stock Picks Right Now
03/28/24	Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
03/27/24	Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
03/27/24	Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
03/12/24	Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
02/26/24	Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
02/15/24	Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
12/14/23	Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
11/09/23	Aeterna Zentaris Reports Third Quarter 2023 Financial Results
10/11/23	Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
09/05/23	Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

AEZS Chatroom

beerjetz Posted - 06/28/24

$AEZS $2 AS SOON!!! 🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣

NotHopeJustFacts Posted - 06/27/24

@Newfieslayer101 sure just call customer service and get your refund from $AEZS

npng Posted - 06/26/24

$AEZS so.. we have a new CEO! Nice! This means that we go again under $1👌🏼👌🏼👌🏼

livendi Posted - 06/25/24

$AEZS 1 of the biggest pos company,look at the lifetime chart,we all lost with this pos but at least i got out before big damage happened,we would be millionares if we had shorted this pos from its inception,what a farce.thanx for nothing klauss,God bless and good luck people

Newfieslayer101 Posted - 06/25/24

$AEZS new CEO salary is almost a million bucks. More than double what klause was paid. Hope he's worth it. We can hardly afford to pay his ass

Newfieslayer101 Posted - 06/25/24

$AEZS yo they quietly fired klause Paulini. New CEO is looted as CEO of AEZS prior to the merger with Ceapro. Wtf happend... other than klause loosing our only profitable drug and tanking the shareholder value

Newfieslayer101 Posted - 06/25/24

$AEZS just want my money back. Lost 95% over last 3 years

beerjetz Posted - 06/24/24

$AEZS $2 AS SOON!!! 🚀🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣

TheDarvas Posted - 06/23/24

$AEZS

RealErnFranklin Posted - 06/21/24

The few other bios from canada with similar floats: $CMND 2.9mil $PBM 4.7mil $XRTX 2.6mil $AEZS 2.9mil $EDSA 2.2mil Some obviously diluting already , and some about to pump first. Slow, til, the go. Get on it ready to pump. Xrtx and edsa ready.

WIZARDTRADING Posted - 06/21/24

$AEZS

npng Posted - 06/21/24

$AEZS

WIZARDTRADING Posted - 06/21/24

$AEZS so the test results are postponed until 3rd quarter 2024 ...

Newfieslayer101 Posted - 06/20/24

$AEZS damn. My value has dropped so much I'm soon going to owe them money

WIZARDTRADING Posted - 06/20/24

$AEZS

WIZARDTRADING Posted - 06/20/24

$AEZS what was the enviable news?

beerjetz Posted - 06/20/24

$AEZS $2 AS SOON!!! 🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣🤣

npng Posted - 06/20/24

$AEZS Piece of shiiitttt! Back to 2$ again.

Hy7543dxc Posted - 06/20/24

$AEZS ㅗ_ㅗ fuc...k you다 18

mamamamama Posted - 06/19/24

$AEZS Wow, the reverse split really attracted new investors. Great job

Bloomsb Posted - 06/19/24

$AEZS US rotten market... no chance. Typical crush so RS needed than lure more innocents than crush again another RS so the current investors never get their money back... most companies 95% don't even survive... Stay away from US market. List in Chinese market

Bloomsb Posted - 06/17/24

Newfieslayer101 Posted - 06/17/24

$AEZS bruh. This stock just straight up not having a good time

beerjetz Posted - 06/14/24

$AEZS $2 AS SOON!!!!!! 🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣

Stock_Titan Posted - 06/13/24

$AEZS Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency https://www.stocktitan.net/news/AEZS/aeterna-zentaris-announces-last-patient-last-visit-in-pivotal-detect-lsbdc0t5aze2.html

Aviannn Posted - 06/12/24

$AEZS can this really go up?

WIZARDTRADING Posted - 06/12/24

$AEZS

Bloomsb Posted - 06/12/24

WIZARDTRADING Posted - 06/07/24

$AEZS this is always making moves

beerjetz Posted - 06/07/24

$AEZS $2 AS SOON!!!!! 🚀🚀🚀🚀🚀🚀